Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]
News [2728]
Articles [201]
Editorials [1]
Conferences [136]
elearning [13]
Addition of platinum to standard neoadjuvant chemotherapy improves EFS in...
Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India
Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC ( Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India )
12 Dec 2022
Treatment decision guided by CTC count may improve long-term outcomes for mBC
Prof Jean-Yves Pierga - Institut Curie, Paris, France
Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )
9 Dec 2022
The concept of pan-tumour therapeutics
Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany
The concept of pan-tumour therapeutics ( Dr Benedikt Westphalen - Comprehensive Cancer Center München, Munich, Germany )
7 Dec 2022
Complex technologies for advanced diagnosis and precision medicine in oncology
Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain
Complex technologies for advanced diagnosis and precision medicine in oncology ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )
24 Oct 2022
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for...
Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )
27 Sep 2022
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
21 Sep 2022
ESMO 2022: Breast and ovarian trial analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
14 Sep 2022
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible...
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York...
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )
14 Sep 2022
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first...
Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )
14 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
ESMO 2022: Renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2022: Renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Fruquintinib provides improvement in overall survival for refractory mCRC
Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA
Fruquintinib provides improvement in overall survival for refractory mCRC ( Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA )
12 Sep 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation